Semaglutide vs. Tirzepatide

Are semaglutide and tirzepatide the same drug?

No — they are two different molecules from two different manufacturers. Semaglutide is a single-hormone GLP-1 receptor agonist made by Novo Nordisk; tirzepatide is a dual GIP and GLP-1 receptor agonist made by Eli Lilly [1], [2], [3], [4].

They belong to the same broad family of incretin medicines and are given the same way — a once-weekly injection — but tirzepatide adds a second mechanism, which is the leading reason its weight-loss numbers come out higher when the two are tested directly against each other [5].

Ozempic, Wegovy, Mounjaro, Zepbound: which brand is which

Most of the confusion in this comparison comes from brand names. Each molecule is sold under different brands for different uses:

• Semaglutide → Ozempic (type 2 diabetes injection), Wegovy (weight-management injection), and Rybelsus (oral diabetes tablet) [3], [4].
• Tirzepatide → Mounjaro (type 2 diabetes injection) and Zepbound (weight-management and sleep-apnea injection) [1], [2].

So "semaglutide vs. tirzepatide" is really "Ozempic/Wegovy vs. Mounjaro/Zepbound." If you've been comparing Ozempic with Mounjaro, or Wegovy with Zepbound, you are comparing these same two molecules — the trial evidence below applies the same way.

What is semaglutide? (Ozempic, Wegovy, Rybelsus)

Semaglutide is a GLP-1 receptor agonist sold under three brand names: Ozempic (a once-weekly injection for type 2 diabetes, now also approved to slow kidney-disease progression in type 2 diabetes), Wegovy (a once-weekly injection for chronic weight management), and Rybelsus (a daily oral tablet for type 2 diabetes) [3], [4].

For weight loss specifically, the relevant version is Wegovy, which titrates to 2.4 mg once weekly. In its pivotal obesity trial, STEP 1, semaglutide produced a mean −14.9% of body weight at 68 weeks, versus −2.4% on placebo [8].

What is tirzepatide? (Mounjaro, Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist — sometimes nicknamed a "twincretin" — sold as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management and, since 2024, obstructive sleep apnea in adults with obesity) [1], [2]. For weight loss, the relevant version is Zepbound, which titrates up to 15 mg once weekly.

In its pivotal obesity trial, SURMOUNT-1, tirzepatide produced up to −20.9% of body weight at the 15 mg dose over 72 weeks [7].

How they work: one hormone vs. two

Both drugs mimic GLP-1, a natural gut hormone released after eating — it curbs appetite, slows how fast the stomach empties, and prompts insulin release when blood sugar is high [3], [1]. Tirzepatide adds a second action: it also activates the GIP receptor, another incretin hormone involved in how the body processes food and energy.

This dual mechanism is the leading explanation for why tirzepatide tends to produce greater weight loss and blood-sugar lowering than a GLP-1-only drug, although exactly how GIP adds benefit is still being studied [5], [6].

Effectiveness: which works better for weight loss?

Tirzepatide produced more weight loss than semaglutide in the one trial that tested them head-to-head. In SURMOUNT-5, 751 adults with obesity but without diabetes were randomized to the highest tolerated dose of each drug.

At 72 weeks, the tirzepatide group lost a mean −20.2% of body weight versus −13.7% on semaglutide, and tirzepatide users were more likely to reach every milestone — ≥10%, ≥15%, ≥20%, and ≥25% loss [5].

To put that gap in real terms: for someone weighing about 250 lb at the start, −20.2% is roughly 50 lb lost, versus about 34 lb at −13.7% — a difference of around 16 lb, on average, between the two drugs. Both results are far beyond what older weight-loss medications achieve, but the dual-agonist edge is real and consistent.

The same pattern shows up in diabetes: in SURPASS-2, tirzepatide beat semaglutide on both blood-sugar control and weight reduction at every dose tested [6].

The bottom line is that across the head-to-head evidence, tirzepatide is the stronger drug for weight loss — but semaglutide still produces substantial, clinically meaningful loss and remains an excellent option for many people, especially where it is better covered by insurance or where its cardiovascular outcome data matter [4], [5], [9].

What to expect: timeline and titration

Neither drug works overnight. Both start at a low dose and step up roughly every 4 weeks, and most of the weight comes off gradually. People often notice reduced appetite and "food noise" within the first few weeks, but meaningful weight loss builds over months as the dose climbs.

In the trials, average weight loss was still increasing at 72 weeks — about 16–17 months — which is when the headline figures were measured [5], [7]. Loss then tends to slow and plateau as the body settles at a new set point.

Both are long-term treatments: when people stop, appetite returns and much of the lost weight typically comes back, which is why clinicians manage obesity as a chronic condition over years rather than a short course [4], [5].

Dosing & administration

Both are once-weekly subcutaneous injections in prefilled pens, started at a low dose and titrated up roughly every 4 weeks to limit nausea [1], [2], [3], [4].

Semaglutide dosing

Wegovy (weight management): 0.25 → 0.5 → 1 → 1.7 → 2.4 mg once weekly. Ozempic (diabetes) tops out at 2 mg. Rybelsus is a separate daily oral tablet (7 or 14 mg) [3], [4].

Tirzepatide dosing

Mounjaro and Zepbound both use the same ladder: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg once weekly [1], [2].

Side effects & safety

Side-effect profiles are very similar because both act on the same GLP-1 pathway — predominantly gastrointestinal, usually mild-to-moderate, and worst in the weeks right after starting or moving up a dose [1], [2], [5].

Common side effects (both)

Nausea, diarrhea, vomiting, constipation, and abdominal pain. In the SURMOUNT-5 head-to-head, gastrointestinal events were the most common in both groups and most were mild to moderate [5].

Serious risks & boxed warning

Both carry a boxed warning for thyroid C-cell tumors seen in rodents, and both are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 [1], [2], [3], [4].

Less common but serious risks for both include pancreatitis, gallbladder disease, acute kidney injury (often from dehydration due to vomiting or diarrhea), and — when combined with insulin or a sulfonylurea — low blood sugar [1], [2], [3], [4].

Who should not take these (and key cautions)

These medications are not for everyone. Both are contraindicated if you or a close family member has had medullary thyroid carcinoma or MEN 2, or if you've had a serious allergic reaction to the drug [1], [2], [3], [4].

Use caution — or avoid — with a history of pancreatitis, gallbladder disease, or severe gastrointestinal disease; semaglutide's label also flags monitoring for diabetic retinopathy [3]. Because semaglutide stays in the body for weeks, it should be stopped at least 2 months before a planned pregnancy [4].

And tirzepatide can make oral birth control less effective — its label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase [1], [2]. Share your full history with your clinician before starting either drug.

What about muscle loss?

As with any substantial weight loss — from any method — part of what you lose on either drug is lean mass, not just fat. There is no strong evidence that one of these two medications spares muscle better than the other.

The established ways to protect muscle are eating enough protein and doing regular resistance training, which is one reason a medically supervised program pairs these medications with nutrition and activity guidance rather than relying on the drug alone.

Cost & insurance coverage

At list price, both run roughly $1,000–$1,350 per month before insurance [1], [2], [3], [4]. Coverage is the real swing factor: plans more often cover the diabetes brands (Ozempic, Mounjaro) for diagnosed type 2 diabetes than the weight-management brands (Wegovy, Zepbound) for obesity alone.

Manufacturer savings programs and self-pay options can lower the real cost meaningfully, and a supervised medical weight-loss program like JumpstartMD's can change what you actually pay.

A note on compounded versions: compounded GLP-1 medications can be a lower-cost route, and the rules around them shifted as the recent shortages resolved [10]. Quality and physician oversight vary by source, so a compounded option should come from a licensed, supervised medical program using a reputable compounding pharmacy — not an anonymous online seller.

JumpstartMD prescribes and supervises these medications, including compounded options where appropriate.

Can you switch between them?

Yes — switching between semaglutide and tirzepatide is common and is done under medical supervision. A clinician will typically restart the dose ladder for the new drug rather than match milligrams (the two are different molecules and are not milligram-equivalent) and manage side effects through the re-titration.

You should not take both at once: combining tirzepatide with a GLP-1 medication like semaglutide is not recommended [2].

Which is right for you?

• Your main goal is maximum weight loss → tirzepatide has the strongest head-to-head evidence [5].
• You have type 2 diabetes → both are highly effective; the choice often comes down to insurance coverage and your other health goals [1], [3].
• Cardiovascular risk is a priority → semaglutide (Wegovy) has the proven outcome data in obesity to date, from the SELECT trial [9].
• You have obstructive sleep apnea with obesity → tirzepatide (Zepbound) is FDA-approved for that specific combination [2].

The right answer depends on your diagnosis, insurance, history, and goals — which is exactly what a supervised consultation sorts out. JumpstartMD physicians prescribe and manage both semaglutide and tirzepatide, including dose titration and side-effect management.